Baseimmune is at the forefront of vaccine development, utilizing a unique combination of scientific expertise and a proprietary AI platform to create mutation-resistant vaccines. Their approach integrates genomic, proteomic, epidemiological, and immunological data to facilitate the generation of multi-target de novo antigens. This innovative methodology allows Baseimmune to model pathogen evolution and immune responses, enabling the design of vaccines that can effectively address emerging and complex pathogens that have historically been overlooked by traditional vaccine strategies. The company emphasizes the importance of maintaining vaccine efficacy in the face of pathogen mutations, aiming to produce multi-strain and multi-species vaccines that offer longer-lasting protection.

Founded in 2019 by a team of experts in vaccine development and software engineering, Baseimmune has made significant strides in the field. Their early-stage pipeline includes promising candidates such as a universal malaria vaccine and a pan-coronavirus vaccine, alongside a veterinary vaccine targeting African Swine Fever. These candidates are currently being tested using advanced methodologies, including mRNA/lipid nanoparticle (LNP) and viral vector technologies. By leveraging computational approaches pioneered by their founders at the Jenner Institute, Baseimmune is committed to accelerating the discovery of novel and cross-protective vaccines, positioning itself as a leader in the fight against infectious diseases.

United Kingdom

Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.

Baseimmune

Company Details